Table 2 Comparison between MVI = 0 and MVI = 1 in the training cohort

Age in years^#

60 (53–65)

58 (50–63)

.128

Sex

.440

No. of men

130 (81.8)

51 (77.3)

No. of women

29 (18.2)

15 (22.7)

Liver disease

.434

HBV infection

141 (88.7)

61 (92.4)

HCV infection

6 (3.8)

3 (4.5)

Other

12 (7.5)

2 (3.0)

Maximum diameter^#

41 (26.5–63.5)

55 (34.3–88.5)

.002*

Tumor margin

 < .001*

Non-smooth

65 (40.9)

44 (59.1)

Smooth

94 (66.7)

22 (33.3)

Cirrhosis

.916

Cirrhosis-negative

100 (62.9)

42 (63.6)

Cirrhosis-positive

59 (37.1)

24 (36.4)

Arterial peritumoral enhancement

.030*

Arterial peritumoral enhancement-negative

40 (25.2)

8 (12.1)

Arterial peritumoral enhancement-positive

119 (74.8)

58 (87.9)

Tumor number

.005*

Solitary

132 (83.0)

43 (65.2)

Multiple

27 (17.0)

23 (34.8)

Laboratory findings^#

AST (IU/mL)

30.6 (27–40.6)

31.9 (26.9–40.5)

.343

ALT (IU/mL)

33.4 (25.2–48.0)

30.6 (24.2–39.6)

.643

RBC (10^12/L)

4.5 (4.2–4.6)

4.5 (4.3–4.7)

.057

Hemoglobin (g/L)

139.5 (129.0–146.8)

142.0 (135.0–148.5)

.017*

Platelet (10^9/L)

149.7 (112.7–173.0)

149.5 (116.2–182.5)

.657

TBil (µmol/L)

14.0 (11.4–16.6)

14.6 (12.0–17.5)

.043*

DBil (µmol/L)

4.3 (3.2–5.2)

4.5 (3.5–5.5)

.040*

Total protein (g/L)

67.3 (64.1–70.7)

67.1 (64.2–70.0)

.597

Albumin (g/L)

39.8 (38.0–41.1)

38.8 (37.9–40.9)

.517

CRP (mg/L)

4.5 (3.3–5.6)

4.9 (3.5–10.9)

.199

ALBI grade

.110

1

89 (56.0)

29 (43.9)

2 or 3

70 (44.0)

37 (56.1)

Tumor markers^#

AFP (ng/mL)

181.3 (5.1–325.2)

325.2 (36.1–1000.0)

.002*

CEA (ng/mL)

1.8 (0.9–1.9)

1.5 (0.7–2.1)

.671

CA242 (U/mL)

5.6 (3.1–6.6)

3.9 (2.5–6.6)

.698